.Pharmacolibrary.Drugs.ATC.J.J05AB18 .Pharmacolibrary.Drugs.ATC.J.J05AB18| name: | Molnupiravir |
| ATC code: | J05AB18 | route: | oral |
| n-compartments | 1 |
Molnupiravir is an oral antiviral prodrug of the ribonucleoside analog N4-hydroxycytidine. It inhibits replication of SARS-CoV-2, the virus responsible for COVID-19. It is used for the treatment of mild to moderate COVID-19 in adults at risk of progressing to severe disease. It has received emergency use authorization in some regions.
Pharmacokinetic parameters in healthy adult volunteers (median age 25-52 years) after oral administration, single dose, fasting state.
Pagliano, P, et al., & Conti, V (2022). The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19). Expert opinion on drug discovery 17(12) 1299–1311. DOI:10.1080/17460441.2022.2153828 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36508255
Chawla, A, et al., & Stone, JA (2023). Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes. Clinical pharmacology and therapeutics 113(6) 1337–1345. DOI:10.1002/cpt.2895 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37017631
Nakamura, K, et al., & Uemura, N (2022). A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19. Clinical and translational science 15(11) 2697–2708. DOI:10.1111/cts.13395 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36053806